Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track...

Related Keywords

Spain ,Alexandra Weingarten ,Troy Wilson ,Nasdaq ,Kura Oncology Inc ,Drug Administration ,Globenewswire Inc ,Linkedin ,Exchange Commission ,Corporate Communications ,Breakthrough Therapy Designation ,Chief Executive Officer ,Orphan Drug Designation ,Vice President ,Investor Relations ,Breakthrough Therapy ,Markets ,